# Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients

> **NCT01150097** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 284 (actual)

## Conditions studied

- Liver Transplant Recipient

## Interventions

- **DRUG:** Tacrolimus (reduced tacrolimus)
- **DRUG:** Everolimus (reduced tacrolimus)
- **DRUG:** Tacrolimus (tacrolimus elimination)
- **DRUG:** Everolimus (tacrolimus elimination)
- **DRUG:** Tacrolimus (tacrolimus control)
- **DRUG:** Corticosteroids

## Key facts

- **NCT ID:** NCT01150097
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03-31
- **Primary completion:** 2013-05-03
- **Final completion:** 2013-05-03
- **Target enrollment:** 284 (ACTUAL)
- **Last updated:** 2018-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01150097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01150097, "Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT01150097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*